607 related articles for article (PubMed ID: 30694875)
21. A prospective head-to-head comparison of
Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhu Z
Eur J Nucl Med Mol Imaging; 2022 Oct; 49(12):4218-4227. PubMed ID: 35657429
[TBL] [Abstract][Full Text] [Related]
22. Comparison of 18F-FDG and 68Ga DOTATATE PET/CT in localization of tumor causing oncogenic osteomalacia.
Agrawal K; Bhadada S; Mittal BR; Shukla J; Sood A; Bhattacharya A; Bhansali A
Clin Nucl Med; 2015 Jan; 40(1):e6-e10. PubMed ID: 24999675
[TBL] [Abstract][Full Text] [Related]
23. Clinical and Prognostic Value of PET/CT Imaging with Combination of
Zhang P; Yu J; Li J; Shen L; Li N; Zhu H; Zhai S; Zhang Y; Yang Z; Lu M
Contrast Media Mol Imaging; 2018; 2018():2340389. PubMed ID: 29681780
[TBL] [Abstract][Full Text] [Related]
24. The Clinical Utility of Gallium-68-DOTATATE Positron Emission Tomography Scanning in Medullary Thyroid Cancer.
Gild ML; Kumar S; Fuchs TL; Glover A; Sidhu S; Sywak M; Tsang V; Gill AJ; Robinson BG; Schembri G; Clifton-Bligh RJ; Hoang J
Endocr Pract; 2024 Mar; 30(3):218-224. PubMed ID: 38103829
[TBL] [Abstract][Full Text] [Related]
25. Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma.
Conry BG; Papathanasiou ND; Prakash V; Kayani I; Caplin M; Mahmood S; Bomanji JB
Eur J Nucl Med Mol Imaging; 2010 Jan; 37(1):49-57. PubMed ID: 19662413
[TBL] [Abstract][Full Text] [Related]
26. [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer.
Vrachimis A; Stegger L; Wenning C; Noto B; Burg MC; Konnert JR; Allkemper T; Heindel W; Riemann B; Schäfers M; Weckesser M
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1765-72. PubMed ID: 27059853
[TBL] [Abstract][Full Text] [Related]
27. Systematically evaluating DOTATATE and FDG as PET immuno-imaging tracers of cardiovascular inflammation.
Toner YC; Ghotbi AA; Naidu S; Sakurai K; van Leent MMT; Jordan S; Ordikhani F; Amadori L; Sofias AM; Fisher EL; Maier A; Sullivan N; Munitz J; Senders ML; Mason C; Reiner T; Soultanidis G; Tarkin JM; Rudd JHF; Giannarelli C; Ochando J; Pérez-Medina C; Kjaer A; Mulder WJM; Fayad ZA; Calcagno C
Sci Rep; 2022 Apr; 12(1):6185. PubMed ID: 35418569
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids.
Jindal T; Kumar A; Venkitaraman B; Meena M; Kumar R; Malhotra A; Dutta R
Cancer Imaging; 2011 Jun; 11(1):70-5. PubMed ID: 21697027
[TBL] [Abstract][Full Text] [Related]
29. The diagnostic and prognostic role of combined [
Albano D; Dondi F; Bauckneht M; Albertelli M; Durmo R; Filice A; Versari A; Morbelli S; Berruti A; Bertagna F
Eur Radiol; 2023 Jun; 33(6):4167-4177. PubMed ID: 36482218
[TBL] [Abstract][Full Text] [Related]
30. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
31. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of
Adnan A; Basu S
J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
[TBL] [Abstract][Full Text] [Related]
32. The potential utility of [
Lan L; Liu H; Wang Y; Deng J; Peng D; Feng Y; Wang L; Chen Y; Qiu L
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):963-979. PubMed ID: 34410435
[TBL] [Abstract][Full Text] [Related]
33. Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.
Ozkan ZG; Kuyumcu S; Uzum AK; Gecer MF; Ozel S; Aral F; Adalet I
Nucl Med Commun; 2015 Mar; 36(3):242-50. PubMed ID: 25369749
[TBL] [Abstract][Full Text] [Related]
34. Detection of Atherosclerotic Inflammation by
Tarkin JM; Joshi FR; Evans NR; Chowdhury MM; Figg NL; Shah AV; Starks LT; Martin-Garrido A; Manavaki R; Yu E; Kuc RE; Grassi L; Kreuzhuber R; Kostadima MA; Frontini M; Kirkpatrick PJ; Coughlin PA; Gopalan D; Fryer TD; Buscombe JR; Groves AM; Ouwehand WH; Bennett MR; Warburton EA; Davenport AP; Rudd JH
J Am Coll Cardiol; 2017 Apr; 69(14):1774-1791. PubMed ID: 28385306
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
[TBL] [Abstract][Full Text] [Related]
36. F-18 FDG uptake on positron emission tomography as a predictor for lymphovascular invasion in patients with lung adenocarcinoma.
Noda Y; Goshima S; Kanematsu M; Watanabe H; Kawada H; Kawai N; Ono H; Bae KT
Ann Nucl Med; 2016 Jan; 30(1):11-7. PubMed ID: 26337532
[TBL] [Abstract][Full Text] [Related]
37.
El-Maouche D; Sadowski SM; Papadakis GZ; Guthrie L; Cottle-Delisle C; Merkel R; Millo C; Chen CC; Kebebew E; Collins MT
J Clin Endocrinol Metab; 2016 Oct; 101(10):3575-3581. PubMed ID: 27533306
[TBL] [Abstract][Full Text] [Related]
38. Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on
Zidan L; Iravani A; Kong G; Akhurst T; Michael M; Hicks RJ
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):204-216. PubMed ID: 32572559
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of hitherto unknown brain meningioma detected on
Parghane RV; Talole S; Basu S
World J Nucl Med; 2019; 18(2):160-170. PubMed ID: 31040748
[TBL] [Abstract][Full Text] [Related]
40. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
